Portola Pharmaceuticals, Inc.
PTLA
PTLA was delisted on the 1st of July, 2020.
150 hedge funds and large institutions have $1.11B invested in Portola Pharmaceuticals, Inc. in 2016 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 52 increasing their positions, 46 reducing their positions, and 18 closing their positions.
111% more call options, than puts
Call options by funds: $17.1M | Put options by funds: $8.1M
13% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 46
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 18
1% less funds holding
Funds holding: 151 → 150 (-1)
1% less capital invested
Capital invested by funds: $1.12B → $1.11B (-$10.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$16.9M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$13.5M |
| 3 |
Millennium Management
New York
|
+$12M |
| 4 |
WC
Weatherbie Capital
Boston,
Massachusetts
|
+$11.7M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$11.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$20.8M |
| 2 |
DM
Deerfield Management
New York
|
-$19.2M |
| 3 |
Goldman Sachs
New York
|
-$12.9M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$11.8M |
| 5 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$6.81M |
PTLA Hedge Fund Activity: Q4 2016 in Review
150 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Portola Pharmaceuticals, Inc. (PTLA) for Q4 2016, worth a combined $1.11B — down 0.97% from $1.12B a quarter earlier.
Fund positioning in PTLA was balanced in Q4 2016: 18 funds opened new positions, 18 closed out, 52 added to existing stakes and 46 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $16.9M. The largest seller was Redmile Group, exiting entirely with an estimated $20.8M sold.
- 150 institutional investors held Portola Pharmaceuticals, Inc. (PTLA) as of Q4 2016, down from 151 in Q3 2016.
- Funds reported $1.11B of Portola Pharmaceuticals, Inc. stock for Q4 2016, down 0.97% quarter-over-quarter.
- 18 funds opened new Portola Pharmaceuticals, Inc. positions in Q4 2016 and 18 closed out, a net change of 0 holders.
- The largest Portola Pharmaceuticals, Inc. buyer in Q4 2016 was Morgan Stanley, an estimated $16.9M added.
- The largest Portola Pharmaceuticals, Inc. seller in Q4 2016 was Redmile Group, an estimated $20.8M sold.
Based on aggregated 13F filings for Q4 2016.